Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
07:05am, Monday, 24'th Nov 2025
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
07:06pm, Friday, 14'th Nov 2025
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $1.5 per share a year ago.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Hold” from Brokerages
01:31am, Sunday, 26'th Oct 2025
Clearside Biomedical, Inc. (NASDAQ: CLSD - Get Free Report) has earned a consensus recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Fiv
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
08:05am, Tuesday, 26'th Aug 2025
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
06:31pm, Friday, 08'th Aug 2025
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
07:05am, Wednesday, 23'rd Jul 2025
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Micr
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
07:05am, Tuesday, 17'th Jun 2025
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 29'th May 2025
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
07:05am, Wednesday, 21'st May 2025
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
06:35pm, Wednesday, 14'th May 2025
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 14'th May 2025
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexibl
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Supra
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
07:05am, Thursday, 08'th May 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapi
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
11:08am, Thursday, 01'st May 2025
Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
